SHANDONG XINHUA (00719.HK): secretary to cut up to 83,300 shares
- Cao Changqiu holds 333,200 shares, or 0.048% of the Company's total share capital; the proposed reduction is capped at 83,300 shares, or 0.012%.
- The reduction period runs from 5 November 2026 to 4 February 2027, with prices determined by the market at the time of the reduction.
NewTimeSpace News: On 13 October 2026, Shandong Xinhua Pharmaceutical Company Limited (stock code: 00719.HK) published an overseas regulatory announcement on a pre-disclosure announcement regarding the shareholding reduction by a senior management member, to be published on cninfo.com.cn on 14 October 2026.
Board secretary Cao Changqiu holds 333,200 shares, or 0.048% of the Company's total share capital, and plans to reduce his holding by no more than 83,300 shares, or 0.012% of the total share capital, through centralised bidding within three months after 15 trading days from the date of this announcement. The reduction is due to personal funding needs, and the shares were all granted under equity incentives. The reduction period runs from 5 November 2026 to 4 February 2027, at market prices. The Company said the plan will not result in a change of control and will not materially affect its governance, shareholding structure or continuing operations.
- SHANDONG XINHUA (00719.HK): Obtains Drug Registration Certificate for Levocarnitine Oral Solution
- SHANDONG XINHUA (00719.HK): Azithromycin Tablets Pass Generic Drug Consistency Evaluation
- SHANDONG XINHUA (00719.HK): Dapoxetine Hydrochloride Tablets Obtain Drug Registration Certificate, Enriching Formulation Portfolio
- SHANDONG XINHUA (00719.HK): Obtains Drug Registration Certificate for Dapagliflozin Tablets
- Shandong Xinhua Pharmaceutical Company Limited (00719.HK): LXH-2103 Injection Approved for Clinical Trials
